Teva’s Multiple Sclerosis Pill Faces EU Verdict
by Bloomberg Industries
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) is expected to issue a decision on Teva/Active Biotech’s pill, laquinimod, for relapsing multiple sclerosis (MS). The CHMP meets Jan. 20-23, and will publish its opinions by Jan. 24. Laquinimod is important for Teva because its injectable MS drug Copaxone, which faces generic competition, has made up close to 20 percent of its revenue. The MS market is also moving toward pills, which have better safety, tolerability and convenience.